Literature DB >> 14623767

Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide.

R De Matteo1, C N May.   

Abstract

Increased circulating levels of adrenomedullin (ADM) cause peripheral vasodilatation and hypotension, accompanied by cardiac actions including tachycardia and increases in cardiac contractility, cardiac output, coronary conductance (CC) and coronary blood flow (CBF). It is unclear to what extent these cardiac effects are direct actions of ADM or secondary to the hypotension and altered cardiac loading. The direct cardiac actions of ADM were examined in conscious sheep previously implanted with aortic and coronary flow probes, and an indwelling left coronary artery cannula. Responses to infusion of ADM (0.5 microg kg(-1) h(-1) for 1 h) into the left coronary artery or jugular vein were compared (n=6). The effect of blockade of nitric oxide (NO) synthase with intracoronary (i.c.) N(omega)-nitro-l-arginine (l-NNA; 1.5 mg kg(-1) h(-1), infused for 2 h before and during ADM infusion, was assessed to determine whether the responses to ADM were mediated by NO (n=5). I.c. ADM caused large and sustained increases in CC (0.35+/-0.07-0.55+/-0.13 ml min(-1) mmHg-1, P<0.05) and CBF (28+/-6-42+/-9 ml min(-1), P<0.05), but had no effect on arterial pressure or indices of cardiac contractility (first differential of the upstroke of systole and peak aortic flow rate). Intravenous infusion of ADM had no effects. I.c. l-NNA, at a dose that abolished the coronary vasodilator action of acetylcholine, blocked ADM-induced coronary vasodilatation. In conclusion, ADM had a direct coronary vasodilator action that was mediated by release of endogenous NO and resulted in increased CBF. There was no evidence for a direct inotropic action of ADM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623767      PMCID: PMC1574158          DOI: 10.1038/sj.bjp.0705572

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats.

Authors:  B D Nossaman; C J Feng; A D Kaye; B DeWitt; D H Coy; W A Murphy; P J Kadowitz
Journal:  Am J Physiol       Date:  1996-05

2.  Cardiovascular actions of adrenomedullin in conscious sheep.

Authors:  D G Parkes
Journal:  Am J Physiol       Date:  1995-06

3.  Evaluation of a transit-time system for the chronic measurement of blood flow in conscious sheep.

Authors:  J A Bednarik; C N May
Journal:  J Appl Physiol (1985)       Date:  1995-02

4.  Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells.

Authors:  Y Shimekake; K Nagata; S Ohta; Y Kambayashi; H Teraoka; K Kitamura; T Eto; K Kangawa; H Matsuo
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

5.  Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1beta and tumor necrosis factor-alpha.

Authors:  T Horio; T Nishikimi; F Yoshihara; N Nagaya; H Matsuo; S Takishita; K Kangawa
Journal:  Endocrinology       Date:  1998-11       Impact factor: 4.736

6.  Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells.

Authors:  Y Ishizaka; Y Ishizaka; M Tanaka; K Kitamura; K Kangawa; N Minamino; H Matsuo; T Eto
Journal:  Biochem Biophys Res Commun       Date:  1994-04-15       Impact factor: 3.575

7.  An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat.

Authors:  A A Owji; D M Smith; H A Coppock; D G Morgan; R Bhogal; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

8.  Plasma adrenomedullin concentration in patients with heart failure.

Authors:  J Kato; K Kobayashi; T Etoh; M Tanaka; K Kitamura; T Imamura; Y Koiwaya; K Kangawa; T Eto
Journal:  J Clin Endocrinol Metab       Date:  1996-01       Impact factor: 5.958

9.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure.

Authors:  M Jougasaki; C M Wei; L J McKinley; J C Burnett
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

10.  Increased plasma adrenomedullin levels in chronic congestive heart failure.

Authors:  K Kobayashi; K Kitamura; T Etoh; Y Nagatomo; M Takenaga; T Ishikawa; T Imamura; Y Koiwaya; T Eto
Journal:  Am Heart J       Date:  1996-05       Impact factor: 4.749

View more
  5 in total

Review 1.  Molecular regulation of tumor angiogenesis and perfusion via redox signaling.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

2.  Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock.

Authors:  Bettina Temmesfeld-Wollbrück; Bernhard Brell; István Dávid; Martin Dorenberg; Jörn Adolphs; Bernd Schmeck; Norbert Suttorp; Stefan Hippenstiel
Journal:  Intensive Care Med       Date:  2007-02-22       Impact factor: 17.440

3.  Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.

Authors:  J B Pawlak; S E Wetzel-Strong; M K Dunn; K M Caron
Journal:  Peptides       Date:  2016-12-08       Impact factor: 3.750

4.  CGRP, adrenomedullin and adrenomedullin 2 display endogenous GPCR agonist bias in primary human cardiovascular cells.

Authors:  Ashley J Clark; Niamh Mullooly; Dewi Safitri; Matthew Harris; Tessa de Vries; Antoinette MaassenVanDenBrink; David R Poyner; Davide Gianni; Mark Wigglesworth; Graham Ladds
Journal:  Commun Biol       Date:  2021-06-23

5.  Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models.

Authors:  Natalie O Karpinich; Samantha L Hoopes; Daniel O Kechele; Patricia M Lenhart; Kathleen M Caron
Journal:  Curr Hypertens Rev       Date:  2011-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.